2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2880

Distinct Metabolic Pathways Regulate Lipid Antigen Presentation By Monocytes and B Cells: Implications for SLE Patients with Pre-Clinical Atherosclerotic Plaque
Abstract Number: 2881

Reduced Hippocampal-Thalamic Fiber Tracts in Systemic Lupus Erythematosus
Abstract Number: 2882

CD4+ T Helper Cells and Regulatory T Cells in Active Lupus Nephritis – an Imbalance Towards a Predominant Th1 Response?
Abstract Number: 2883

The CD4+CD52low T Cell Contributes to the Development of Systemic Lupus Erythematosus through the CCR8/TARC Pathway
Abstract Number: 2884

Cell-Type Specific Epigenetic Features of Systemic Lupus Erythematosus
Abstract Number: 2885

Expression Levels and Function of the Inhibitory Molecule, Immunoglobulin like Transcript 7 (ILT7), Are Decreased on Circulating Plasmacytoid Dendritic Cells in SLE Patients with High ANA Titers
Abstract Number: 2886

Associations Between Type I Interferon and Antiphospholipid Antibody Status Differ Between Ancestral Backgrounds
Abstract Number: 2887

Clinical Predictors for Development of Interstitial Lung Disease in Mixed Connective Tissue Disease
Abstract Number: 2888

Usefulness of Bosentan in the Prevention of Pulmonary Hypertension in Patients with Systemic Sclerosis
Abstract Number: 2889

Therapeutic Plasma Exchange for the Treatment of Raynaud’s and Digital Ulcers in Systemic Sclerosis: A Systematic Review
Abstract Number: 2890

Feasibility of Same Day Adipose Tissue Harvest, Cell Processing and Subcutaneous Delivery of Adipose Derived Regenerative Cells into Fingers of Scleroderma Patients within a Randomized Double Blind Clinical Trial
Abstract Number: 2891

Prognostic Significance of Autoantibody Positivity in Interstitial Lung Disease: A Retrospective Case-Control Study
Abstract Number: 2892

Serum Level of KL-6, a Biomarker of Interstitial Lung Disease (ILD), Is Higher in Diffuse SSc Than in Limited SSc and RA Even When the Activity of ILD Is Low
Abstract Number: 2893

Usefulness of the Eustar Preliminary Criteria for Vey Early Systemic Sclerosis and Le Roy Criteria for Early-Systemic Sclerosis in Identifying Patients at Risk of Development of Systemic Sclerosis
Abstract Number: 2894

Efficacy of Rituximab in Systemic Sclerosis with Interstitial Lung Disease

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].